TRDA
Entrada Therapeutics Inc
NASDAQ: TRDA · HEALTHCARE · BIOTECHNOLOGY
$14.50
+7.41% today
Updated 2026-05-01
Market cap
$503.12M
P/E ratio
—
P/S ratio
19.79x
EPS (TTM)
$-3.47
Dividend yield
—
52W range
$5 – $14
Volume
0.2M
Entrada Therapeutics Inc (TRDA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $25.26M | $129.01M | $210.78M | $25.42M |
| Revenue growth (YoY) | — | — | — | — | +410.7% | +63.4% | -87.9% |
| Cost of revenue | $104000.00 | $326000.00 | $1.12M | $1.90M | $99.88M | $3.77M | $4.10M |
| Gross profit | $-104000.00 | $-326000.00 | $-1.12M | $-1.90M | $129.01M | $210.78M | $21.32M |
| Gross margin | — | — | — | -7.5% | 100.0% | 100.0% | 83.9% |
| R&D | $8.22M | $21.10M | $35.93M | $66.61M | $99.88M | $125.31M | $142.27M |
| SG&A | $3.61M | $5.57M | $15.20M | $30.64M | $32.29M | $38.47M | $41.05M |
| Operating income | $-11.82M | $-26.67M | $-51.13M | $-97.25M | $-3.16M | $47.01M | $-156.00M |
| Operating margin | — | — | — | -385.0% | -2.5% | 22.3% | -613.7% |
| EBITDA | $-11.72M | $-26.20M | $-50.01M | $-95.35M | $-321000.00 | $50.78M | $-142.40M |
| EBITDA margin | — | — | — | -377.5% | -0.2% | 24.1% | -560.2% |
| EBIT | $-11.82M | $-26.52M | $-51.13M | $-97.25M | $-3.16M | $47.01M | $-142.83M |
| Interest expense | $0.00 | $0.00 | $31000.00 | $2.63M | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-4.65M | $-26.52M | $-50.07M | $-87.46M | $-6.68M | $65.63M | $-143.75M |
| Net income growth (YoY) | — | -470.5% | -88.8% | -74.7% | +92.4% | +1081.7% | -319.0% |
| Profit margin | — | — | — | -346.2% | -5.2% | 31.1% | -565.5% |